Not Yet RecruitingNCT06923891
Xanomeline and trospium for people with early-stage schizophrenia
About this title
Read the official source — NCT06923891This study evaluates the effectiveness of Xanomeline/Trospium for people with schizophrenia.
Medication studyAges 18–40United States
Understand this study
What is this study about?
This study evaluates the effectiveness of Xanomeline/Trospium for people with schizophrenia.
Who could participate?
Listed age limits: 18 years to 40 years.
- Listed locations
- RichmondSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: April 16, 2025
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 172
- Sponsor
- Vanguard Research Group
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 40 Years
- Official registry ID
- NCT06923891
- Official title
Show the full official title
An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients
Recruitment & locations
Not yet recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Richmond
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the effectiveness of Xanomeline/Trospium for people with schizophrenia.
Who is behind this study?
The study sponsor is Vanguard Research Group.
Does this study involve medication?
Yes. The study involves medication, including Xanomeline/Trospium.
Who can participate?
Listed age limits: 18 years to 40 years.
Is this study still recruiting?
The registry lists this study as not yet recruiting.
